Homologous recombination deficiency (HRD) is associated with increased sensitivity to PARP inhibitors (PARPi), which offer improved progression-free survival (PFS) in HRD-positive patients compared to those with homologous recombination proficiency (HRP). The gene discussed is PARP1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.